Age and treatment choices in advanced colorectal cancer
作者： Sunita J Padman , Timothy J Price
DOI: 10.2217/CRC.12.36
关键词: Medicine 、 Colorectal cancer 、 Oncology 、 Chemotherapy 、 Treatment choices 、 Advanced colorectal cancer 、 Optimal management 、 Cancer 、 Disease 、 Tolerability 、 Internal medicine 、 Surgery
摘要: SUMMARY Colorectal cancer is primarily a disease of the elderly. During past 15 years, median survival for metastatic colorectal has increased significantly. Older patients are heterogeneous population, and chronological age not reliable predictor tolerance treatment. There now significant body evidence that demonstrates equal efficacy tolerability treatment between older younger patients. Despite this, chemotherapy use declines with advancing age. Further research needed to enable optimal management this group
futuremedicine.com
sci-hub.se 参考文章(53)
Sylvia E. Furner, Jacob A. Brody, Linda M. Jankowski, Epidemiology and Aging Springer, New York, NY. pp. 37- 43 ,(1997) , 10.1007/978-1-4757-2705-0_3
, Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis BMJ. ,vol. 321, pp. 531- 535 ,(2000) , 10.1136/BMJ.321.7260.531
Valérie Quipourt, Valérie Jooste, Vanessa Cottet, Jean Faivre, Anne-Marie Bouvier, Comorbidities Alone Do Not Explain the Undertreatment of Colorectal Cancer in Older Adults: A French Population-Based Study Journal of the American Geriatrics Society. ,vol. 59, pp. 694- 698 ,(2011) , 10.1111/J.1532-5415.2011.03334.X
S Earlam, C Glover, M Davies, C Fordy, T G Allen-Mersh, Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. Journal of Clinical Oncology. ,vol. 15, pp. 2022- 2029 ,(1997) , 10.1200/JCO.1997.15.5.2022
Paulo M. Hoff, Rafat Ansari, Gerald Batist, John Cox, Walter Kocha, Mario Kuperminc, Jean Maroun, David Walde, Charles Weaver, Evelyn Harrison, Hans U. Burger, Bruno Osterwalder, Alfred O. Wong, Ralf Wong, Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study Journal of Clinical Oncology. ,vol. 19, pp. 2282- 2292 ,(2001) , 10.1200/JCO.2001.19.8.2282
C Twelves, Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. European Journal of Cancer. ,vol. 38, pp. 15- 20 ,(2002) , 10.1016/S0959-8049(01)00415-4
I Chau, A R Norman, D Cunningham, J S Waters, C Topham, G Middleton, M Hill, P J Ross, R Katopodis, G Stewart, J R Oates, Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. British Journal of Cancer. ,vol. 91, pp. 1453- 1458 ,(2004) , 10.1038/SJ.BJC.6602169
Martine Extermann, Ivette Boler, Richard R. Reich, Gary H. Lyman, Richard H. Brown, Joseph DeFelice, Richard M. Levine, Eric T. Lubiner, Pablo Reyes, Frederic J. Schreiber, Lodovico Balducci, Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score Cancer. ,vol. 118, pp. 3377- 3386 ,(2012) , 10.1002/CNCR.26646
David Hamerman, Toward an Understanding of Frailty Annals of Internal Medicine. ,vol. 130, pp. 945- 950 ,(1999) , 10.7326/0003-4819-130-11-199906010-00022
R. Adams, R. Wilson, M.T. Seymour, A.M. Meade, A. Madi, J. Cassidy, D. Fisher, S. Kenny, R. Kaplan, T.S. Maughan, 15LBA Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN) Ejc Supplements. ,vol. 7, pp. 10- 10 ,(2009) , 10.1016/S1359-6349(09)72050-6